News | Radiopharmaceuticals and Tracers | May 22, 2017

Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18

Companies also announce the extension and expansion of their existing commercial supply agreement for nuclear products through 2020

Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18

May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a definitive license agreement  for the continued Phase III development and worldwide commercialization of flurpiridaz F-18. Flurpiridaz F-18 is an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent that may improve the diagnosis of coronary artery disease (CAD), the most common form of heart disease. The definitive agreement follows the signing of a term sheet previously announced in late February 2017.

Under the definitive agreement, GE Healthcare will lead and fund the development program of flurpiridaz F-18, including the second Phase III clinical study. GE Healthcare will also have exclusive worldwide rights for the commercialization of flurpiridaz F-18. Lantheus will collaborate in both the development and commercialization process through a joint steering committee. Lantheus also maintains the option to co-promote the agent in the United States.

Lantheus will receive a $5 million upfront cash payment and, if successful, up to $60 million in regulatory and sales milestones payments, plus double-digit royalties on U.S. sales and single-digit royalties on sales outside of the U.S.

Separately, the companies have also extended and expanded their current commercial agreement under which Lantheus will continue to supply GE Healthcare with TechneLite (Technetium Tc99m Generators), Gallium-67 (Gallium Citrate Ga 67 Injection) and Xenon-133 (Xenon Xe 133 Gas) through Dec. 31, 2020.

For more information: www.gehealthcare.com, www.lantheus.com

Related Content

Sponsored Content | Videos | Cybersecurity | December 12, 2017
J.
Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017
Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology,...
Toshiba Vantage Galan 3T XGO Edition MRI Features New Advanced Gradient

MRI of the brain performed on the Galan 3T utilizing the 32-channel Head SPEEDER Coil

Technology | Magnetic Resonance Imaging (MRI) | December 11, 2017
Toshiba Medical, a Canon Group company, demonstrated the Vantage Galan 3T XGO Edition with the all-new Saturn X...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Philips Debuts IQon Elite Spectral CT Scanner at RSNA 2017
Technology | Computed Tomography (CT) | December 11, 2017
At the 2017 Radiological Society of North America (RSNA) Annual Meeting, Philips unveiled the IQon Elite Spectral CT,...
Siemens Healthineers Introduces Mammomat Revelation Mammography System for Improved Biopsy Workflow
Technology | Mammography | December 11, 2017
Siemens Healthineers unveiled the new Mammomat Revelation premium mammography platform at the 2017 Radiological Society...
Breast Cancer Screening Performance Impacted by Mean Mammographic Compression Pressure
News | Mammography | December 08, 2017
Dutch researchers demonstrated a strong relationship between compression pressure in mammography and breast cancer...
Sponsored Content | Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Technology | Neuro Imaging | December 07, 2017
Deep learning artificial intelligence (AI) medical company DeepRadiology  announced the world's first computed...
Sponsored Content | Videos | Advanced Visualization | December 07, 2017
Dianna Bardo M.D., director of body MR and co-director of the 3-D Innovation Lab at Phoenix Children's Hospital.
Overlay Init